Following promising pre-clinical trials at the University of Southampton, Biolnvents B1-1206 (a new fully-human antibody) is to enter a collaborative phase I/II for patients with chronic lymphocytic leukaemia and non Hodgkin lymphoma.
B1206 is an antibody that not only kills tumour cells directly but has also shown to prevent cancer cells from becoming resistant to Rituximab (a successful state of the art treatment).
“Monoclonal antibodies have boosted survival rates for many types of lymphoma and leukaemia in recent years, but patient responses remain varied. BI-1206 has shown great promise in reducing treatment resistance in the laboratory. Leukaemia & Lymphoma Research has funded research into this treatment at the University of Southampton since 2008 and we’re very excited that through this partnership patients could benefit from it soon” said Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research.
Read full article:
http://www.cancertechnology.co.uk/bioinvents-bi-1206-antibody-enter-collaborative-trial